Arrowstreet Capital
CSTL icon

Arrowstreet Capital’s Castle Biosciences CSTL Stock Holding History

Arrowstreet Capital’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.21M Buy
92,736
+65,594
+242% +$1.46M ﹤0.01% 1506
2026
Q1 		$666K Buy
27,142
+20,113
+286% +$659K ﹤0.01% 1620
2025
Q4 		$273K Buy
+7,029
New +$227K ﹤0.01% 1747
2025
Q1 		– Sell
-28,903
Closed -$770K – 1846
2024
Q4 		$770K Buy
+28,903
New +$880K ﹤0.01% 1506

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Arrowstreet Capital's CSTL Position: Q2 2026 in Review

Arrowstreet Capital increased its Castle Biosciences (CSTL) stake by 242% in Q2 2026, buying an estimated $1.46M and bringing the position to 92,736 shares worth $2.21M. The position accounts for ﹤0.01% of the portfolio, ranked #1506.

Arrowstreet Capital first reported a position in CSTL in Q4 2024 and has held it in 4 quarters since. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Arrowstreet Capital held 92,736 shares of Castle Biosciences worth $2.21M as of Q2 2026.
  • Arrowstreet Capital bought 65,594 Castle Biosciences shares in Q2 2026, an estimated $1.46M.
  • Castle Biosciences made up ﹤0.01% of Arrowstreet Capital's portfolio in Q2 2026, its #1506 holding.
  • Arrowstreet Capital first reported a position in Castle Biosciences in Q4 2024 and has held it in 4 quarters since.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.